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Abstract
Since 2012, the United States has experienced a biennial spike in pediatric acute flaccid myelitis 
(AFM).1–6 Epidemiologic evidence suggests non-polio enteroviruses (EVs) are a potential 
etiology, yet EV RNA is rarely detected in cerebrospinal fluid (CSF).2 We interrogated CSF from 
children with AFM (n=42) and pediatric other neurologic disease controls (n=58) for intrathecal 
anti-viral antibodies using a phage display library expressing 481,966 overlapping peptides 
derived from all known vertebrate and arboviruses (VirScan). We also performed metagenomic 
next-generation sequencing (mNGS) of AFM CSF RNA (n=20 cases), both unbiased and with 
targeted enrichment for EVs. Using VirScan, the only viral family significantly enriched by the 
CSF of AFM cases relative to controls was Picornaviridae, with the most enriched Picornaviridae 
peptides belonging to the genus Enterovirus (n=29/42 cases versus 4/58 controls). EV VP1 ELISA 
confirmed this finding (n=22/26 cases versus 7/50 controls). mNGS did not detect additional EV 
RNA. Despite rare detection of EV RNA, pan-viral serology identified frequently high levels of 
CSF EV-specific antibodies in AFM compared to controls, providing further evidence for a causal 
role of non-polio EVs in AFM.
Introduction
First detected in California in 2012, the United States has experienced seasonal, biennial 
increases in the incidence of acute flaccid myelitis (AFM) cases.7 Since 2014, the Centers 
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for Disease Control and Prevention (CDC) has reported over 500 confirmed cases.1–4,8 The 
nationwide surges in AFM in 2014, 2016, and 2018 have coincided temporally and 
geographically with outbreaks of enterovirus (EV) D68 and EV-A71 infections.2,6,9–11 EVs, 
including poliovirus, are well recognized for their neuroinvasive capacity and resultant 
central nervous system (CNS) pathology, ranging from self-resolving aseptic meningitis to 
fulminant, sometimes fatal, brainstem encephalitis, and to myelitis leading to permanent 
debilitating paralysis.12
Despite the temporal association between EV-D68 and EV-A71 outbreaks and AFM and a 
mouse model that recapitulates the AFM phenotype with a contemporary EV-D68 strain,13 
the etiology of AFM has been difficult to confirm.14,15 Thus, concerns persist that AFM 
could result from yet-to-be-identified pathogens or a para-infectious immune response. This 
is due, in part, to the fact that less than half of children with AFM have had EV detected in a 
non-sterile biologic specimen (nasopharyngeal or oropharyngeal swabs most commonly, 
rectal and stool samples less commonly), and no other alternative candidate etiologic agents 
have been identified in the remaining children.3 In addition, only 2% of children with AFM 
have EV nucleic acid detected in cerebrospinal fluid (CSF).16,17
The immune privileged status of the CNS makes direct detection of viral nucleic acid or 
indirect discovery of intrathecal anti-viral antibodies an important step in linking a pathogen 
to a neuroinfectious disease. We interrogated CSF from AFM patients from recent outbreaks 
with unbiased ultra-deep metagenomic next-generation sequencing (mNGS), including a 
novel CRISPR-Cas9 based enrichment technique called FLASH (Finding Low Abundance 
Sequences by Hybridization).18 Furthermore, to search for virome-wide antibody signals 
that might be associated with AFM, we employed the VirScan approach that was previously 
developed to detect antibodies to all known human viruses.19 To improve upon this detection 
method, we generated a large and more finely tiled peptide library in the T7 bacteriophage 
display vector described in detail in Methods.
Results
Cases and Controls
42 AFM cases and 58 other neurologic disease (OND) controls were included in the study 
(Extended Data 1). Patient demographics are described in Table 1 with detailed information 
on available clinical diagnostic testing in Supplemental Tables 1A and 1B. The AFM cases 
were younger (median age 37.8 months, interquartile range [IQR], 11 to 64 months) than the 
OND controls (median age 120 months, IQR, 66 to 174 months), with a p-value of 0.0497 
(as determined by an unpaired parametric t-test). There was a higher proportion of males in 
the AFM cases. AFM cases and OND controls from the Western and Northeastern USA 
make up the majority of both categories. Most AFM cases were from 2018.
Ultra-Deep Metagenomic Next-Generation Sequencing Rarely Detects Enterovirus in AFM
We obtained an average of 433 million 150 nucleotide (nt) paired-end reads per sample 
(range, 304 – 569 million reads per sample). Based on the External RNA Controls 
Consortium (ERCC) RNA spike-ins, we estimated that our mean limit of detection was 5.48 
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attograms (range, 3.92 to 17.47 attograms).20 EV-A71 was detected in one AFM sample at 
71.31 reads per million (rpM) (1497.3 rpM in FLASH-NGS, Supplemental Tables 2 and S3). 
This sample was previously known to be EV-A71 positive by EV RT-PCR and Sanger 
sequencing. No other pathogenic organisms were detected in this or any of the other AFM 
samples. The non-human sequence reads from each sample were deposited at the National 
Center for Biotechnology Information Sequence Read Archive (PRJNA557094).
CSF VirScan Testing Detects Enterovirus Antibodies in AFM
The only significantly enriched viral family by VirScan of CSF in AFM cases (n = 42) 
versus OND controls (n = 58) was Picornaviridae (mean rpK 11,082, IQR 16,850 versus 
mean rpK 1121 IQR 974, p-adjusted = 6.3 × 10−8 Mann-Whitney test with Bonferroni 
adjustment, Supplemental Table 4). Enriched Picornaviridae peptides belonged almost 
entirely to the genus Enterovirus (Figure 1A–C, Supplemental Table 5), with 69% (29/42) of 
AFM cases versus 7% (4/58) of OND controls considered positive for EV antibodies by 
VirScan. Enriched EV peptides were derived from proteins across the EV genome (Figure 
2A, Supplemental Table 6A). Peptides mapping to Sapelovirus and unclassified 
Picornaviridae were also significantly enriched in AFM relative to OND controls (p-adjusted 
= 0.013 and 0.00038, respectively by Mann-Whitney test with Bonferroni adjustment). 
Using the EV-A71 genome as a model reference EV as in Figure 2A, 99% and 95% of the 
rpK signal for Sapelovirus and unclassified Picornaviridae mapped to EV-A71 using 
BLASTP (e-value threshold 0.01, word size 2) (Supplemental Tables 6B and C).
Among capsid protein sequences, KVPALQAAEIGA in VP1 was previously reported to be 
an immunodominant linear EV epitope.21,22 Peptides containing this and related overlapping 
epitopes were enriched in our data across AFM patients, with multiple sequence alignment 
revealing a consensus motif of PxLxAxExG (Figure 2B). Another immunodominant epitope 
was to a conserved, linear portion of 3D (Figure 2C).
Enterovirus VP1 ELISA confirms VirScan Findings
Consistent with the VirScan data, the mean EV VP1 ELISA signal in AFM (n = 26, mean 
OD 0.51 IQR 0.56) was significantly higher than OND controls (n = 50, mean OD 0.08 IQR 
0.06, p-value < 0.001 by Mann-Whitney test, Figure 3 and per-patient data in Supplemental 
Tables 1A and 1B). The EV signal detected by phage and ELISA demonstrated a linear 
correlation (R2 = 0.511, p-value < 0.001, Extended Data 2). Among AFM patients, mean 
CSF EV antibody levels detected by either ELISA or VirScan did not differ based on 
whether EV RNA had been previously detected (n =15) or not (n = 11) (mean OD 0.41 
versus 0.65 by ELISA; mean rpK 6,093 vs 14,489 by VirScan, p-value = not significant for 
both comparisons). In total, 85% (22/26) of a subset of AFM versus 14% (7/50) of OND 
tested by ELISA demonstrated reactivity against VP1. ELISA confirmed 18/19 EV positive 
VirScan samples and identified 11 additional EV positive samples. Additional samples 
detected by ELISA did have EV phage signal by VirScan but were below the conservative 
threshold we used for designating a sample as a positive (Supplemental Tables 1A and 1B).
We did not observe an obvious independent effect of geography, year, or season on either the 
VirScan total EV enrichment or the ELISA VP1 EV data (Extended Data 3–5). To the extent 
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that the magnitude of CSF pleocytosis is a surrogate for the degree of inflammation and 
associated blood-brain barrier compromise, we found no correlation between the CSF cell 
count and the magnitude of EV antibodies as measured by either VirScan or VP1 ELISA 
(Extended Data 6A). Further, we found no relationship between the total CSF IgG 
concentration and the results of EV antibody testing by either VirScan or ELISA (Extended 
Data 6B). In addition, there was no difference observed in the total CSF IgG concentration 
between the subset of the AFM cases and OND controls for whom clinical laboratory data 
were available (Extended Data 6C). We did not observe a relationship between the input 
VirScan library and our immunoprecipitation results (Extended Data 7).
We attempted to identify serologic signatures specific to EV-A71 or EV-D68 using both 
VirScan and VP1 ELISA, but both assays yielded cross-reactivity in patients with known EV 
infections due to either EV-A71 or EV-D68 (Extended Data 8). Indeed, CSF from AFM 
cases were commonly enriched for antibodies targeting more than one EV species (Extended 
Data 9, Supplemental Tables 1A and 1B).
Discussion
We combined unbiased ultra-deep mNGS with an adaptation of the VirScan method for 
comprehensively detecting anti-viral antibodies to query CSF from a relatively large (n=42) 
and geographically diverse subset of children presenting with AFM since 2014.19 Ultra-deep 
mNGS combined with FLASH enrichment for EV-A71 and EV-D68 confirmed the presence 
of EV RNA in a single sample that was previously known to be positive for EV-A71 by PCR 
and failed to discover any other pathogen in this or other AFM CSF samples. There are a 
number of possible reasons for the lack of detectable EV nucleic acid in the CSF of AFM 
patients by mNGS or other methods. Clinically, radiologically and similarly to poliomyelitis, 
the CNS tissue involved in AFM is often restricted to the anterior horn cells in the cervical 
spinal cord, making it possible that little to no virus is shed into the CSF. In addition, 
children with AFM, especially when associated with EV-D68, typically present with 
neurologic symptoms a median of 5–7 days after prodromal illness onset, decreasing the 
probability of RNA detection.23
Lack of consistent identification of viral nucleic acid in CSF is not limited to AFM, rather it 
is common to a wide range of neuroinvasive viruses, including poliovirus, rabies virus, West 
Nile virus, and other arboviruses.24 As a result, detection of intrathecal antibody production 
through CSF serologic testing is the gold standard for diagnosis of many neuroinvasive 
viruses, notably West Nile virus and varicella-zoster virus.25,26 Thus, we supplemented CSF 
mNGS with VirScan to comprehensively profile CSF anti-viral antibodies in AFM cases and 
OND controls. VirScan revealed high levels of CSF immunoreactivity to immunodominant 
EV epitopes in AFM, independent of whether EV RNA had previously been detected in 
clinical testing of CSF or nonsterile sites. There was a non-significant trend towards greater 
enrichment of EV antibodies in patients without directly detectable virus in a peripheral site, 
however, possibly owing to the rise in titer that occurs in the weeks following an infection. 
Independent testing with EV-A71 and EV-D68 VP1 ELISAs confirmed these findings. 
VirScan and whole VP1 ELISA were not able to consistently identify specific individual EV 
types, likely owing to cross-reactive immune responses to conserved linear EV antigens.27 
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Future studies using well-folded virus, rather than linear phage display peptides or 
individual viral proteins, may be more fruitful for identifying a species-specific serologic 
signature.
This study has important limitations. First, detection of a serologic response to a virus at a 
single time point by itself does not fulfill Koch’s postulates for establishing causality 
between a virus and a particular disease. Nonetheless, these serologic data support the 
specificity of the CSF antibody response to EVs in AFM, helping fulfill the Bradford Hill 
criteria for making a causal association.14,15 Second, further work will be necessary to 
establish, in a prospective manner, the diagnostic sensitivity and specificity for CSF EV 
serology. Third, our cases and controls were not optimally matched. While the controls had a 
diversity of pediatric ONDs, the case and control cohorts were not similar by age, year, or 
season, which are important risk factors for EV infection in the United States. However, we 
did not see a significant effect of year or season on EV signal by VirScan or ELISA in the 
OND controls. We chose to report these preliminary findings, despite the limitations of the 
study design, because of the public health urgency of understanding the etiology of AFM. A 
prospective study with matched cases and controls is necessary to confirm our findings.
AFM is a potentially devastating neurologic syndrome whose incidence of reported cases 
has risen in the US since 2014 with biennial peaks. In addition, cases have now been 
detected in 14 other countries across 6 continents.23 There are no proven treatments for 
AFM, and like poliomyelitis, a vaccine may ultimately be the most effective prevention 
strategy. However, it is important to first achieve consensus around the likely etiologic 
agents. While continued vigilance for other possible etiologies of AFM is warranted, 
together our combined mNGS, VirScan, and viral protein ELISA interrogation of AFM CSF 
supports the notion that EV infection likely underlies the majority of AFM cases tested in 
this study. These results offer a roadmap for rapid development of EV CSF antibody assays 
to enable efficient clinical diagnosis of EV-associated AFM in the future.
Methods
Detailed methods for data collection, human subjects review, mNGS, VirScan, 
bioinformatics, and independent confirmatory testing with ELISA are provided in the 
Supplemental Appendix.
Case-Control Design
All AFM cases met the 2018 US Council of State and Territorial Epidemiologists case 
definition for probable or confirmed AFM (Supplemental Table 7).28 Patient samples were 
collected with informed consent either through enrollment in research studies or through 
public health surveillance. In addition, residual banked CSF was obtained from children with 
other neurologic diseases (ONDs) without suspected primary EV infection and without 
known exposure to intravenous gamma globulin for controls.
Metagenomic Sequencing Library Preparation
CSF was shipped on dry ice to our laboratory and stored immediately upon receipt at −80°C 
until use. RNA sequencing libraries were prepared using a previously described protocol 
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optimized and adapted for miniaturization and automation.29 Libraries were sequenced on a 
NovaSeq 6000 machine (Illumina) to generate 150 nucleotide (nt), paired-end reads. 
Samples were also sequenced after enrichment for EV-A71 and EV-D68 genomes using 
FLASH (Finding Low Abundance Sequences by Hybridization, Supplemental Table 2).18 
All NGS libraries were depleted of host ribosomal RNA with DASH (Depletion of 
Abundant Sequences by Hybridization) and spiked-in with External RNA Controls 
Consortium (ERCC) sequences as previously described.20,30
Metagenomic Bioinformatics
As previously described, pathogens were identified from raw mNGS sequencing reads using 
IDseq v3.2, a cloud-based, open-source bioinformatics platform designed for detection of 
microbes from mNGS data.31
Pan-Viral CSF Serologic Testing with VirScan
The previously published VirScan method is an application of programmable phage 
immunoprecipitation-sequencing (PhIP-Seq), displaying viral peptides on the outer surface 
of bacteriophage for the purposes of antibody detection followed by deep sequencing.19,32 
Similarly, we constructed a T7 bacteriophage display library comprised of 481,966 sixty-two 
amino acid peptides with a 14 amino acid overlap tiled across a representative set of full-
length, vertebrate, mosquito-borne, and tick-borne viral genomes downloaded from the 
UniProt and RefSeq databases in February 2017 (Supplemental Table 8A–D). After 
amplification, phage libraries were incubated with 2 μL of patient CSF overnight and then 
immunoprecipitated for two rounds as previously described.33,34 Barcoded phage DNA was 
sequenced on a HiSeq 4000 machine (Illumina) using 150 nt paired-end reads.
VirScan Bioinformatics
Sequencing reads were aligned to a reference database comprising the full viral peptide 
library. Peptide counts were normalized by dividing by the sum of counts and multiplying by 
100,000 (reads per hundred thousand (rpK)).33–36 Phage rpK results for each phage in each 
subject were filtered using a cutoff fold-change of greater than 10 above the mean 
background rpK generated from null IPs (Supplemental Table 9). A sample was considered 
EV positive if the total EV rpK value was greater than the mean signal in the OND controls 
plus one standard deviation.
Independent Validation with ELISA
To independently validate our VirScan results, we generated recombinant viral protein 1 
(VP1) from recent AFM-associated EV-A71 and EV-D68 strains and performed ELISA to 
detect EV antibodies with AFM CSF samples for which sufficient CSF remained (n=26) and 
OND controls (n=50). Signal was measured as the optical density (OD) at 450 nm and 
reported after background subtraction (background OD = 0.05). For each sample, we 
considered the higher of the two (EV-A71 or EV-D68) OD values when analyzing cases and 
controls. A sample was considered positive if the reported OD was greater than three times 
the background.
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Statistical Methods
VirScan data comparisons between AFM cases and OND controls were made using the 
Mann-Whitney test with Bonferroni adjustment for multiple comparisons, n=42 AFM cases 
and n=58 OND controls. EV VP1 signal by ELISA was compared between n=26 AFM cases 
and n=50 OND controls using the Mann-Whitney test. When subsets were tested, exact n 
and statistical tests are provided in figure legends. All error bars are defined in figure 
legends.
Data Availability Statement—VirScan and clinical data analyzed in the manuscript have 
been made available in the online supplementary material. The non-human sequence reads 
from the mNGS experiments for each sample were deposited at the National Center for 
Biotechnology Information Sequence Read Archive (PRJNA557094).
Extended Data
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Extended Data Fig. 1. Flow chart depicting patient enrollment by institution
mNGS with and without FLASH were performed on CSF samples acquired from the CDC 
(n=14 AFM, n=4 OND, n=2 EV positive controls) and UCSF AFM Cohort (n=6 AFM). 
Samples from all institutions were tested by VirScan. Due to limited sample, a subset of 
those tested by VirScan were tested by confirmatory ELISA.
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Extended Data Fig. 2. Comparison of VirScan and ELISA
A comparison of the total amount of enterovirus signal generated by VirScan (x-axis) to the 
maximum OD generated by either EV-D68 or EV-A71 signal ELISA (greater of the two 
values shown) for all samples run (n = 26 AFM + 50 OND). The 95% confidence intervals 
are shaded in grey.
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Extended Data Fig. 3. Geographic distribution of cases and controls
Geographic comparison of cases (blue) and controls (orange) with average EV signal by 
ELISA (top), average EV signal by VirScan (middle), and total number (bottom).
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Extended Data Fig. 4. Season and year of cases and controls
Season and year comparison for cases (blue) and controls (orange) with average EV signal 
by ELISA (top), average EV signal by VirScan (middle), and total number (bottom).
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Extended Data Fig. 5. Analysis of effect of year and season on enterovirus signal in the OND 
controls.
EV VirScan (left, n = 54) and EV VP1 ELISA (right, n = 50) for the OND control cohort by 
year (top) and season (bottom). Bar graphs depict heights as median values with error bars 
reflecting the interquartile range. Statistics for year were performed with the Mann-Whitney 
test and for seasons with the Kruskal-Wallis test.
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Extended Data Fig. 6. CSF cell count and IgG concentration in cases and controls do not explain 
EV signal by VirScan or ELISA.
CSF enterovirus antibodies by VirScan a and ELISA are not correlated with the overall 
amount of CNS inflammation as measured by the CSF cell count (panel A) or CSF IgG 
(panel B) in a subset of patients. The 95% confidence intervals for each measurement are 
shaded in blue (ELISA) or red (Virscan). When comparing the concentration of IgG in a 
subset of AFM cases and OND controls, there was no difference in CSF IgG concentration 
(p = ns by Mann-Whitney, mean with errors bars showing standard deviation displayed). 
Two OND CSF IgG values were reported as < 0.9 mg/dL and were conservatively estimated 
to be 0. Errors bars represent 95% confidence intervals.
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Extended Data Fig. 7. Enterovirus antibody enrichment in AFM cases with VirScan is not a 
reflection of bias in the input library.
Dotplot demonstrating replicate IPs from a typical sample (left panel) correlate with each 
other but not with the input library (right panel). Values plotted are log10 of the raw rpK 
values + 1. The sum of the signal at each point on the axes is expressed as a barplot on the 
axes of the graph.
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Extended Data Fig. 8. Strain calling by ELISA versus VirScan
ELISA and VirScan data from subjects with EV-A71 or EV-D68 detected by RT-PCR in 
either CSF, stool or respiratory fluid. Top panels with strain-specific VP1 ELISA data from 
EV-A71 (n = 8, red) and EV-D68 (n = 3, blue) patients show cross reactivity. Bottom panels 
shows VirScan data from known EV-A71 (n = 9, red) and EV-D68 (n = 7, blue) patients. EV-
A and EV-D signals were generated by summing the total rpK generated against EV-A and 
EV-D derived peptides within a sample.
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Extended Data Fig. 9. Enterovirus species per-subject heatmap.
VirScan enterovirus genus signal in each subject demonstrating enrichment for a cross-
reactive EV signal in the AFM subjects (left) as compared with OND (right). Signal 
represents the log base 2 of the subject’s EV rpK value divided by the mean rpK value in the 
OND subjects for each EV species. To increase clarity, resulting values below 3 are not 
shown (legend).
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enterovirus Immunoreactivity in Acute Flaccid Myelitis on a Pan-Viral Phage Display 
Assay.
(A) Viral families detected by VirScan or phage display immunoprecipitation with next-
generation sequencing (PhIP-Seq) sorted by their Baltimore classification. Heatmap color 
intensity was calculated by subtracting the mean reads per hundred thousand sequenced 
(rpK) in the other neurologic disease (OND) cerebrospinal fluid sample set (n=58) from that 
observed in acute flaccid myelitis (AFM) CSF (n=42). The maximum and minimum color 
intensities reflect +11,000 and −11,000 rpK, respectively. The strongest intensity is observed 
in the Picornaviridae family (boldface type). (B) Genus Enterovirus demonstrating the 
strongest enrichment in family Picornaviridae. (C) Violin plot of the proportion of 
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Enterovirus phage per patient with mean and first and third quartile indicated by horizontal 
lines; Mann-Whitney test corrected for multiple comparisons with a Bonferroni adjustment.
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Figure 2. Primary Enterovirus Antigens Identified by Pan-Viral Phage Display in Acute Flaccid 
Myelitis.
We identified 438 unique, enriched antigens with taxonomic identifications mapping to 
enterovirus (EV) across all acute flaccid myelitis (AFM) cerebrospinal fluid samples (n=42). 
(A) 420 of 438 EV derived peptides were mapped by BLASTP to the 2,193 amino acid 
polyprotein of EV-A71 (Genbank Accession AXK59213.1) as a model reference. The 
relative recovery of these peptides by VirScan is plotted as the log2 of the sum of the 
differences in the mean signal generated in the AFM and pediatric other neurologic disease 
(OND) cohorts, using a moving average of 32 amino acids, advanced by 4 amino acid steps. 
(B) Multiple sequence alignment of a representative set of enriched EV-derived peptides for 
the VP1 (blue bar) and 3D (red bar) proteins. Sequences from EV-D68 (Genbank Accession 
AIT52326.1) and EV-A71 (Genbank Accession AXK59213.1) are included for reference. 
Amino acids are shaded to indicate shared identity among peptides from the indicated EV 
species.
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Figure 3. Independent Validation of Pan-Viral Phage Display with Purified Enterovirus VP1 
Capsid Protein.
(A) Violin plot that enterovirus (EV) signal generated by ELISA can be found at similar 
levels in acute flaccid myelitis (AFM) patients with previously detected (n=15) and 
previously undetected (n=11) EV infections (p = ns). In both AFM cohorts, there was a 
significantly greater amount of signal generated by ELISA compared with pediatric other 
neurologic disease (OND) controls (n=50) (p < 0.001 for both comparisons, Mann-Whitney 
test). (B) Similar results by VirScan with no differences seen when comparing EV signal in 
AFM patients with previously detected (n=23) and previously undetected (n=19) EV 
infections (p = ns). When each group was compared to the OND controls (n=58), both 
demonstrated significant enrichment of EV signal (p < 0.001; Mann-Whitney test with 
Bonferroni adjustment for multiple comparisons).
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Table 1.
Characteristics of the Patients at Baseline
AFM Cases OND Controls
N 42 58
Age – median (IQR), months 38 (11 to 64) 120 (66–174)
Sex – no. (%)
Female 13 (31) 32 (55)
Male 29 (69) 26 (45)
Region – no. (%)
United States
West 20 (48) 37 (64)
South 7 (17) 4 (7)
Midwest 3 (7) 4 (7)
Northeast 11 (26) 9 (16)
International
South America 0 (0) 2 (3)
Canada 1 (2) 0 (0)
North Atlantic Island 0 (0) 1 (2)
Middle East 0 (0) 1 (2)
Year – no. (%)
2014 5 (12) 10 (17)
2015 0 (0) 14 (24)
2016 2 (5) 12 (21)
2017 0 (0) 8 (14)
2018 34 (81) 14 (24)
Season – no. (%)
Spring 1 (2) 18 (31)
Summer 12 (29) 8 (14)
Fall 24 (57) 20 (34)
Winter 5 (12) 12 (21)
Suspected Etiology – no. (%)
Infectious - 23 (40)
Autoimmune - 22 (38)
Non-inflammatory - 6 (10)
Malignancy - 3 (5)
Unavailable - 4 (7)
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NB: Percentages may not total 100 because of rounding.
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